Cécile Chartier

3.5k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Cécile Chartier is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Cécile Chartier has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Genetics. Recurrent topics in Cécile Chartier's work include Virus-based gene therapy research (6 papers), CAR-T cell therapy research (6 papers) and Cancer Research and Treatments (3 papers). Cécile Chartier is often cited by papers focused on Virus-based gene therapy research (6 papers), CAR-T cell therapy research (6 papers) and Cancer Research and Treatments (3 papers). Cécile Chartier collaborates with scholars based in United States, France and Belgium. Cécile Chartier's co-authors include A Dieterlé, Andréa Pavirani, Majid Mehtali, Eric Degryse, Murielle Gantzer, Austin Gurney, John Lewicki, Stephanie Smith‐Berdan, Jorge Aguilar and Tim Hoey and has published in prestigious journals such as PLoS ONE, Cancer Research and Journal of Virology.

In The Last Decade

Cécile Chartier

22 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli

1996 591 citations Cécile Chartier, Eric Degryse et al. Journal of Virology profile →

Peers

Countries citing papers authored by Cécile Chartier

Since Specialization

Citations

This map shows the geographic impact of Cécile Chartier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cécile Chartier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cécile Chartier more than expected).

Fields of papers citing papers by Cécile Chartier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cécile Chartier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cécile Chartier. The network helps show where Cécile Chartier may publish in the future.

Co-authorship network of co-authors of Cécile Chartier

This figure shows the co-authorship network connecting the top 25 collaborators of Cécile Chartier. A scholar is included among the top collaborators of Cécile Chartier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cécile Chartier. Cécile Chartier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1053P Iovance generation-2 tumour-infiltrating lymphocyte (TIL) product is reinvigorated during the manufacturing process 2020 ·Annals of Oncology ·Michelle R. Simpson-Abelson, (unknown), (unknown), Maria Fardis, Cécile Chartier	2
2	1052P Genetic modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer 2020 ·Annals of Oncology ·Krit Ritthipichai, (unknown), Alexandre Juillerat, Laurent Poirot, Maria Fardis, Cécile Chartier	13
3	873P In vivo persistence of Iovance tumour-infiltrating lymphocytes LN-145 in cervical cancer patients 2020 ·Annals of Oncology ·Amir A. Jazaeri, Viktoria Gontcharova, Mark A. T. Blaskovich, Kranthi Kunkalla, Emma L. Masteller, Maria Fardis, Cécile Chartier	5
4	Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors 2020 ·Cell and Gene Therapy Insights ·Maria Fardis, (unknown), Friedrich Graf Finckenstein, Cécile Chartier	7
5	WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death 2017 ·Science Advances ·Marcus Fischer, Belinda Cancilla, Vincent Yeung, Fiore Cattaruzza, Cécile Chartier, Christopher L. Murriel, Jennifer Cain, (unknown), Chieh-Yang Cheng, James Evans, Gilbert O’Young, Xiaomei Song, John Lewicki, Ann M. Kapoun, Austin Gurney, Wan-Ching Yen, Timothy Hoey	122
6	Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models 2015 ·Cancer Research ·Fiore Cattaruzza, (unknown), Wan-Ching Yen, Alayne Brunner, Min Wang, (unknown), Marcus Fischer, Gilbert O’Young, Cécile Chartier, Austin Gurney, Tim Hoey, John Lewicki, Ann M. Kapoun	1
7	Françoise Canon-Roger & Christine Chollier, Des genres aux textes : Essais de sémantique interprétative en littérature de langue anglaise 2008 ·Études irlandaises ·Cécile Chartier	0
8	Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy 2008 ·PLoS ONE ·Scott J. Dylla, Lucia Beviglia, In‐Kyung Park, Cécile Chartier, Janak Raval, (unknown), (unknown), Jorge Aguilar, Sasha Lazetic, Stephanie Smith‐Berdan, Michael F. Clarke, Tim Hoey, John Lewicki, Austin Gurney	448
9	Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer 2008 ·PLoS ONE ·Irene Kuhn, Paul Harden, Maxine Bauzon, Cécile Chartier, (unknown), Steve H. Thorne, Tony Reid, Shaoheng Ni, André Lieber, Kerry Fisher, Leonard W. Seymour, Gabor M. Rubanyi, Richard N. Harkins, Terry Hermiston	153
10	Correction: Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy 2008 ·PLoS ONE ·Scott J. Dylla, Lucia Beviglia, Inkyung Park, Cécile Chartier, Janak Raval, (unknown), (unknown), Jorge Aguilar, Sasha Lazetic, Stephanie Smith‐Berdan, Michael F. Clarke, Tim Hoey, John Lewicki, Austin Gurney	39
11	Outcomes for systemic therapy in women with ovarian cancer 2006 ·Gynecologic Oncology ·Laurie Elit, Cécile Chartier, Amit M. Oza, Hal W. Hirte, Mark N. Levine, Lawrence Paszat	15
12	Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus 2005 ·Molecular Therapy ·Peter J. Kretschmer, Fang Jin, Cécile Chartier, Terry Hermiston	11
13	3 Adjuvant phase III trial (EORTC 18871) with RIFN-alpha 2B versus RIFNgamma versus Iscador versus observation for melanoma patients after surgery for high risk primary (>3 mm) or regional lymph node metastasis 2004 ·Melanoma Research ·Ulrich R. Kleeberg, Stefan Suciu, E.‐B. Bröcker, D. J. Ruiter, Cécile Chartier, D. Liénard, J.R. Marsden, (unknown), A.M.M. Eggermont	2
14	Final results of the EORTC 18871/DKG 80-1 randomised phase III trial 2003 ·European Journal of Cancer ·Ulrich R. Kleeberg, Stefan Suciu, E.‐B. Bröcker, D. J. Ruiter, Cécile Chartier, D. Liénard, J.R. Marsden, Dirk Schadendorf, A.M.M. Eggermont	145
15	Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871) 1999 ·European Journal of Cancer ·(unknown), Eva-Bettina Bröcker, F. Lejeune, Cécile Chartier, Christine Egger, J.R. Marsden, (unknown), Stefan Suciu	48
16	Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. 1996 ·PubMed ·(unknown), Florence Dupuit, Cécile Chartier, Nathalie Accart, A Dieterlé, Huguette Schultz, Édith Puchelle, Andréa Pavirani	32
17	Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli breakdown → 1996 ·Journal of Virology ·Cécile Chartier, Eric Degryse, Murielle Gantzer, A Dieterlé, Andréa Pavirani, Majid Mehtali	591
18	Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. 1996 ·PubMed ·Jean‐Luc Imler, Cécile Chartier, Dominique Dreyer, A Dieterlé, (unknown), T. Faure, Andréa Pavirani, Majid Mehtali	47
19	D.N.C.B. for malignant melanoma: significance in the treatment strategy. 1990 ·PubMed ·F. Truchetet, (unknown), (unknown), Cécile Chartier, E Grosshans	9
20	[Atrial natriuretic hormone and regulation of water-electrolyte balance and the circulating blood volume]. 1987 ·PubMed ·Cécile Chartier, (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact